

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number  
**WO 01/26623 A3**

(51) International Patent Classification<sup>7</sup>: A61K 45/06, 31/55, A61P 25/00

(21) International Application Number: PCT/GB00/03926

(22) International Filing Date: 12 October 2000 (12.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9924172.1 12 October 1999 (12.10.1999) GB

(71) Applicant: LAXDALE LIMITED [GB/GB]; Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB).

(72) Inventors: HORROBIN, David, F.; Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB). LODER, Cari; Sunnydene, 10 Silo Road, Farncombe, Surrey GU7 3PA (GB).

(74) Agent: POWELL, Stephen, David; Williams, Powell & Associates, 4 St. Paul's Churchyard, London EC4M 8AY (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:  
21 June 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF FATIGUE, HEAD INJURY AND STROKE

(57) Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack. The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.

AL

# INTERNATIONAL SEARCH REPORT

Int :ional Application No

PCT/GB 00/03926

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K45/06 A61K31/55 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 11009 A (C.LODER) 18 April 1996 (1996-04-18) cited in the application claims 1-5,10,18,20 page 1, line 6-21 ---	1,2,9, 10,12-15
X	WO 98 01157 A (THE WWK TRUST) 15 January 1998 (1998-01-15) cited in the application claims 1,3-9 page 8, line 7-19 page 10, line 3-14 --- -/--	1,2,9, 10,12-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

28 March 2001

Date of mailing of the international search report

06/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Peeters, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03926

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08520 A (SCOTIA HOLDINGS PLC) 5 March 1998 (1998-03-05) cited in the application claims 1-4,6 page 1 page 2, paragraph 1 page 4 page 5, paragraph 1 ----	1-4,9, 10,12-15
X	WO 88 04173 A (SEROTONIN INDUSTRIES OF CHARLESTON) 16 June 1988 (1988-06-16) claims 1,4-6,8,11,12 page 1 ----	1,2,8,9, 13-15
X	WO 98 09623 A (SCOTIA HOLDINGS PLC) 12 March 1998 (1998-03-12) claims 1,2,4,5 page 5, line 1-5 ----	1,2,8,9, 14,15
X	A.P.WORSLEY, J.ALLAWI: "A combined treatment for severe diabetic neuropathy symptoms" DIABETIC MEDICINE, vol. 15, no. 9, 1998, page 797 XP000990770 page 797 -----	1,2,9, 10,13-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/GB 00/03926

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611009 A	18-04-1996	AU 710339 B	16-09-1999
		AU 3612695 A	02-05-1996
		CA 2200761 A	18-04-1996
		CZ 9700995 A	12-11-1997
		EP 0784476 A	23-07-1997
		FI 971290 A	02-06-1997
		GB 2308065 A,B	18-06-1997
		HU 77380 A	28-04-1998
		JP 10508583 T	25-08-1998
		NO 971539 A	04-04-1997
		NZ 293642 A	28-10-1998
		PL 319830 A	01-09-1997
		SK 43897 A	05-08-1998
		US 6096737 A	01-08-2000
		ZA 9508391 A	06-05-1996
WO 9801157 A	15-01-1998	AU 3451797 A	02-02-1998
		CA 2259010 A	15-01-1998
		EP 0942751 A	22-09-1999
WO 9808520 A	05-03-1998	AU 4025397 A	19-03-1998
		EP 1007053 A	14-06-2000
WO 8804173 A	16-06-1988	US 4843071 A	27-06-1989
		AT 91417 T	15-07-1993
		AU 599193 B	12-07-1990
		AU 1042688 A	30-06-1988
		CA 1298201 A	31-03-1992
		DE 3786558 A	19-08-1993
		DE 3786558 D	19-08-1993
		DK 428488 A	01-08-1988
		EP 0334889 A	04-10-1989
		JP 2501065 T	12-04-1990
WO 9809623 A	12-03-1998	AU 4027097 A	26-03-1998

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number  
**WO 01/26623 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 9/00**

(21) International Application Number: **PCT/GB00/03926**

(22) International Filing Date: 12 October 2000 (12.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9924172.1 12 October 1999 (12.10.1999) GB

(71) Applicant: **LAXDALE LIMITED** [GB/GB]; Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB).

(72) Inventors: **HORROBIN, David, F**; Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB). **LODER, Cari**; Sunnysdene, 10 Silo Road, Farncombe, Surrey GU7 3PA (GB).

(74) Agent: **POWELL, Stephen, David**; Williams, Powell & Associates, 4 St. Paul's Churchyard, London EC4M 8AY (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TREATMENT OF FATIGUE, HEAD INJURY AND STROKE**

(57) Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack. The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.

WO 01/26623 A2

## TREATMENT OF FATIGUE, HEAD INJURY AND STROKE

This invention relates to the treatment of neurological disorders and more particularly to the  
5 treatment of neurologically-related fatigue, brain injury, stress, and related conditions.

Some years ago one of us noted that combinations of various types of antidepressants, together with neurotransmitter precursors such as phenylalanine, tyrosine and tryptophan, could improve the symptoms of multiple sclerosis and a patent application covering this  
10 invention was filed (PCT/GB95/02361). Subsequently we and various associates also noticed that these same combinations could improve peripheral neuropathy, pain from peripheral neuropathy and pain of any type (PCT/GB97/01822 and PCT/GB97/02295). In each case vitamin B12, folic acid, pyridoxine and other nutrients could be added to the formulations.

15 We have continued to make clinical observations on the effects of various drugs and amino acids on multiple sclerosis and on pain and as a result have made new discoveries which extend the inventions disclosed in the above patent applications. In particular, we have found that the range of drugs and amino acid precursors which are most effective are those which specifically affect noradrenaline at nerve endings so activating noradrenergic systems, such as  
20 lofepramine, desipramine and reboxetine among the drugs and phenylalanine and tyrosine among the amino acids. Phenylalanine and tyrosine are precursors of noradrenaline. Tryptophan, the serotonin precursor, and drugs which act preferentially on serotonin have some actions but are less effective. Other drugs which are effective in combination with phenylalanine or tyrosine are drugs which are combined inhibitors of both noradrenaline and  
25 serotonin uptake, such as venlafaxine, duloxetine or milnacipran, and drugs which are combined inhibitors of both dopamine and noradrenaline reuptake such as bupropion.

In addition to refining the list of the most effective drugs, the list of possible uses of the combinations has been expanded to include chronic stress, chronic fatigue syndrome,  
30 fibromyalgia, fatigue in association with migraine, fatigue in association with brain injuries or

other forms of brain damage including stroke, and illnesses associated with chronic fatigue such as irritable bowel syndrome. A particularly important new use for the combinations of noradrenergic drug and noradrenaline precursor is the neurological rehabilitation of patients after any form of damage to the brain, including traumatic brain injuries and strokes.

5

Because of the anecdotal evidence of the benefits of lofepramine and phenylalanine, reported in earlier patent applications, we have conducted a substantial, randomised, placebo-controlled, double blind trial in 138 patients with multiple sclerosis (MS). Half the patients received 70mg lofepramine and 500mg l-phenylalanine twice a day, while the other half received identical-appearing placebos. All patients in both groups received regular injections of vitamin B12. 44 patients had the relapsing/remitting type of MS, 35 had primary progressive disease, and 59 had secondary progressive disease. A wide range of disease severities was exhibited by the patients: on the Kurtzke Extended Disability Symptom Scale (EDSS) about half the patients had severities of 6.5 or more, with the other half 6.0 or less.

15

Patients were assessed on various scales, but particularly the Kurtzke scale, and the Gulick MS Patient Symptom scale. The Kurtzke scale aims to provide a relatively objective assessment of the degree of disability as assessed by the neurologist. The Gulick scale assesses a range of symptoms assessed by the patient. These symptoms can be grouped into six factors (Gulick EE, Model confirmation of the MS-related symptom checklist. Nursing Res 1989; 38: 147-153): musculoskeletal (including weakness, spasms and balance problems): elimination (bowel and bladder): emotions (depression, anxiety and loneliness): sensory (pain, numbness, paraesthesia): head symptoms (visual, swallowing and memory): and fatigue. The trial lasted for six months and patients were assessed at baseline, 2 weeks, 4 weeks, 3 months and 6 months.

25

The results were clear cut and surprising and showed the best evidence ever obtained for a treatment for MS, especially given the relatively short duration of the trial. Interferons slow down the rate of deterioration in MS but do not produce any actual improvements in symptoms. As a result trials have to be two or three years long in order to show differences between active and placebo groups: those differences depend not on improvement in the

30

interferon group but on deterioration in the placebo group. In contrast, lofepramine + phenylalanine produced actual improvements both on the Gulick and the Kurtzke scales. The placebo group showed a deterioration in the Kurtzke scale, and a small improvement on the Gulick scale. The results are summarised in table 1.

5

Table 1. The results of the trial for the Kurtzke disability and Gulick symptom scales. In the change from baseline line, a + sign indicates improvement and a - sign indicates deterioration. In the difference between the two groups, a + sign indicates that active treatment with lofepramine and phenylalanine was better than placebo. There were 69 patients in each group.

10

Parameter	Kurtzke	Gulick
Baseline score	6.07	20.02
Change from baseline on active	+0.107	+10.63
Change from baseline on placebo	-0.132	+ 3.68
Difference between active and placebo	+0.239	+ 6.95
P for difference	0.042	0.017

15 Three particularly surprising and striking findings emerged from the results obtained with the Gulick scale. First, the effect was very rapid: there was a clear difference between active and placebo by 2 weeks, which reached a peak at 4 weeks and then stayed stable for the remaining five months of the trial. Second, the improvement was seen across all the sub-scales of the Gulick scale (overall 20.5% from baseline, musculoskeletal 15%, elimination 27%, emotions 20 31%, sensory 23%, head 27% and fatigue 21%): these are large and important effects which have a major impact on the quality of life of patients. Third, the effect on fatigue was particularly important to the patients since it was quick, substantial and a contrast to the interferons which often increase fatigue initially. Patients with MS consistently state that

fatigue is the single most important symptom which affects their quality of life (JD Fisk et al. The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Science 1994; 21: 9-14). We had previously noted an effect on fatigue in a few patients with MS (PCT/GB95/02361) but had not drawn particular attention to this, nor claimed treatment of fatigue, nor expected to see such a large, consistent and statistically significant effect on this important and difficult to manage symptom.

The anecdotal evidence indicating that noradrenaline precursors and noradrenergic drugs like lofepramine and desipramine are particularly effective, and the new and unexpected clinical trial evidence which clearly proves the efficacy, and shows that the effect on fatigue is very important, and that the effects on symptoms are astonishingly rapid and effective across all the symptom groups, has led us to extend our ideas and new applications of those ideas. In particular, the combination of the noradrenaline precursors, phenylalanine and tyrosine, coupled with a drug which either has as its sole action or a component of its action the inhibition of noradrenaline reuptake, is now seen to be valuable in the treatment of fatigue in any form, in the management of rehabilitation after stroke, in the treatment of stress in any form, and in the treatment of fibromyalgia and related disorders such as irritable bowel syndrome.

We can now, as a result of these entirely novel clinical trial findings, draw conclusions about mechanisms of action which lead to these novel applications. First, it is apparent that the system involved is dependent on noradrenaline and to a much smaller extent on serotonin: the greater impact of noradrenergic as opposed to serotonergic drugs, and the greater effect of phenylalanine as opposed to tryptophan, indicate this. Second, the mechanism is extremely rapid and is too quick to involve any major neuroregeneration which is likely to take months or years if it occurs: the mechanism is therefore likely to involve changes in the function of an existing neuronal system within the brain and spinal cord. Third, the wide range of systems improved by the treatment includes neuronal systems supplying the head and neck, the skeletal muscles, the sensory system, the autonomic nervous system and higher cortical

functions: the nerve cells involved in the therapeutic effect must therefore interact with almost all parts of the brain and spinal cord.

What parts of the central nervous system might fulfil the criteria required to explain the effects of lofepramine and phenylalanine? There are two closely related systems which precisely fit our entirely novel and unexpected observations. These are the Locus Coeruleus (LC) and the Lateral Tegmentum (LT) (RY Moore and FE Bloom, Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annual Review of Neuroscience 1979; 2: 113-168. BH Smith and WH Sweet, Monoaminergic regulation of central nervous system function: I. Noradrenergic systems. Neurosurgery 1978; 3: 109-119).

The LT and the LC are unique systems. They are both dependent on noradrenaline (NA, also known as norepinephrine) as their main neurotransmitter. The LC is a neuronal nucleus located in the brainstem reticular formation. The LT is a more diffuse system including a number of nuclei such as the dorsal motor vagus, the nucleus tractus solitarius and adjacent tegmentum, and the lateral tegmentum itself. The nerve fibres of the LC travel virtually throughout the whole central nervous system, including to the spinal cord, brainstem, cerebellum, thalamus, hypothalamus, basal telencephalon and the entire cortex. The LT neurons are somewhat less widely distributed but even so go to the spinal cord, brainstem, hypothalamus and basal telencephalon.

The real peculiarity of these systems, however, relates to (a) their astonishingly frequent neuronal branching so that a single LT or LC nerve cell may have axons which connect with millions of other nerve cells, (b) the diverse endings of branches from a single nerve cell so that one branch may go to the cerebellum, for example, while another goes to the cortex, (c) their lack of clear cut synaptic end targets, with each nerve cell making diffuse contact with millions of other cells, and (d) their release of noradrenaline from sites along all the branches of the axons and not just from the synaptic endings. Smith and Sweet vividly state "single

axons may traverse several regions of the brain, making no specific synaptic connections in any one area, but spraying transmitter (noradrenaline) over several areas”.

5 The axons of the LT and LC systems are very widely distributed, making contact with motor nerve systems, sensory nerve systems, pain systems and autonomic systems such as those regulating cardiovascular and respiratory functions, bladder and bowel functions, reproductive functions and stress responses.

10 It is therefore apparent that the LT and LC systems are primarily noradrenergic systems which are able to influence almost all parts of the rest of the nervous system simultaneously. They are thus very strong candidates for the rapid and completely generalised relief of symptoms obtained in response to lofepramine and phenylalanine in the trial we have just completed in MS.

15 One of the well-known and difficult to explain observations in MS is that the symptoms seen in the patients are often poorly correlated with the precise positions of the lesions in the central nervous system which are identified by magnetic resonance imaging. Some of the symptoms can be directly related to the lesions, but many of the more generalised symptoms and especially the autonomic symptoms and the fatigue are difficult to relate precisely to the  
20 specific points of damage. This situation is similar to that seen in a substantial number of other central nervous system (CNS) disorders. In stroke, head injury, or any form of specific localised damage to the brain, it has long been recognised that there are two syndromes: the first is localised and clearly related to the specific nerve cells damaged by the lesion: the second is much more generalised and includes widespread impairment of neuronal function  
25 and very frequently includes substantial subjective fatigue (JL Ingles et al, Fatigue after stroke, Archives of Physical Medicine and Rehabilitation 1999; 80: 173-177. MG Boyeson et al. Sparing of motor function after cortical injury. Archives of Neurology 1994; 51: 405-413. DM Feeney et al, Noradrenergic pharmacotherapy, intracerebral infusion and adrenal transplantation promote functional recovery after cortical damage. Journal of Neural  
30 Transplantation and Plasticity 1993; 4: 199-213.). These syndromes are in many ways similar

to those which occur in response to prolonged and uncontrollable stress, and also in the rather mysterious syndrome known as chronic fatigue syndrome which is closely related to fibromyalgia and which is associated with a number of other medical conditions including irritable bowel syndrome, and esophageal reflux and related disorders (JM Weiss et al, Behavioral depression produced by an uncontrollable stressor: relationship to norepinephrine, dopamine and serotonin levels in various regions of rat brain. Brain Research Reviews 1981; 3: 167-205. DJ Clauw, Fibromyalgia: more than just a musculoskeletal disease. American Family Physician 1995; 52: 843-851).

10 In all of these conditions there is emerging evidence that the LC and LT systems are dysfunctional. The reasons for the dysfunction may be various. Because the LT and LC neurons go almost everywhere in the CNS, local damage to any part of the CNS will inevitably damage some axons from LT and LC nerve cells. That damage may then impair the function of the LC and LT themselves, or at the least impair the function of the other parts  
15 of the brain innervated by the damaged nerves. For example, many LC neurons have branches going to both the cerebellum and the cerebral cortex. A stroke or injury or an MS lesion affecting the cerebellum may thus alter cortical function and vice versa. Because the LT and LC neurons are an important part of the response to stress, sustained stress may lead to damage to or temporary or permanent exhaustion of the system. Viral infection may  
20 damage the LT and LC systems directly and this, with chronic stress, may be related to some chronic fatigue and fibromyalgia syndromes.

We propose that what lofepramine and phenylalanine are doing is activating the LC and LT system. This explains the effects on fatigue and on the whole range of symptoms in MS,  
25 involving motor, sensory, autonomic and higher cerebral functions. Activation of the LC and LT systems also explains the relief of pain of all types since the LC and LT noradrenergic systems are particularly involved in the regulation of chronic pain (eg CJ Glynn et al, Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury, Lancet 1986; ii: 1249-51. SVR Reddy et al. Spinal cord pharmacology of adrenergic agonist-  
30 mediated antinociception. Journal of Pharmacology and Experimental Therapeutics 1980;

213: 525-533). This mechanism indicates that the treatment will also be effective in chronic stress, chronic fatigue, in fibromyalgia and related conditions, in irritable bowel syndrome and in relieving the general fatigue and neurological symptoms which are seen not just in MS but in almost any illness which involves any form of damage to the brain or spinal cord.

5

#### Case History No.1

An example of the use of our invention was a woman of 41 years of age who had been incapacitated for about 12 years by chronic fatigue syndrome associated with fibromyalgia and irritable bowel syndrome. Until the age of 29 she had been a relatively normal woman,  
10 married with two children. However, she then experienced what appeared to be a mild attack of influenza. Instead of recovering quickly as usual, she became depressed and fatigued and unable to carry out her normal part-time work and care for her children in the usual way. Everything became an effort and she could sustain only short bursts of activity before having to rest. She also developed multiple aches and pains throughout her body, characteristic of  
15 fibromyalgia, and an irritable bowel in which painful spasms alternated with constipation. She was given almost all conceivable treatments over the years, including many types of non-steroidal anti-inflammatory drugs, both tricyclic and serotonin reuptake inhibiting and noradrenaline reuptake inhibiting antidepressants, and even steroids. Some of these treatments produced transient effects but these never lasted. She was then given combined  
20 treatment with lofepramine, 70mg bd and L-phenylalanine, 500mg bd. Over a period of 2-3 weeks she experienced a considerable improvement in fatigue, in fibromyalgia and in her irritable bowel. She and her family expected these effects to wear off but instead they persisted. After six months she was essentially back to her normal self.

25 The implications are important in stroke and brain injury which have remained depressingly resistant to the development of pharmacological interventions. Many recent trials of a wide variety of agents have failed to alter the outcome in stroke or brain injury. However, there are animal studies which are encouraging in this respect. In essence, experimental stroke is associated with inhibition of LC function and the generalised loss of motor function appears  
30 to be caused by a failure of the noradrenergic system (Boyeson et al and Feeney et al, above).

Treatment with noradrenaline facilitates recovery in animals from such lesions and there is preliminary evidence that there may be beneficial effects in humans (Feeney et al and Boyeson et al, above and also, DM Feeney, From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. *Brain Plasticity: Advances in*  
5 *Neurology* 1997; 73: 383-394. MG Boyeson and KA Krobert, Cerebellar norepinephrine infusions facilitate recovery after sensorimotor cortex injury, *Brain Research Bulletin* 1992; 29: 435-439. MG Boyeson & DM Feeney, Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. *Pharmacology Biochemistry and Behavior* 1990; 35: 497-501). Of particular interest, desipramine, which is a metabolite of lofepramine,  
10 is able to enhance LC function and recovery of motor function after brain lesions: in contrast, drugs acting on the serotonin system have much smaller effects. (MG Boyeson & RL Harmon, Effects of trazodone and desipramine on motor recovery in brain-injured rats. *American Journal of Physical Medicine and Rehabilitation* 1993; 72: 286-293. RJ Valentino et al, Antidepressant actions on brain noradrenergic neurons. *Journal of Pharmacology and*  
15 *Experimental therapeutics* 1990; 253: 833-840. MG Boyeson et al. Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury. *American Journal of Physical Medicine and Rehabilitation* 1994; 73: 76-83).

These effects of noradrenergic compounds alone are important but relatively modest. Our  
20 concept of combining a noradrenergic drug like lofepramine or desipramine, together with a noradrenaline precursor such as phenylalanine or tyrosine, is much more effective. This is surprising because many people have tried to enhance noradrenaline synthesis by administering the precursors phenylalanine or tyrosine but have failed. Many studies have shown that in normal humans and animals the administration of phenylalanine or tyrosine has  
25 little or no effect on the synthesis of noradrenaline (JD Milner and RJ Wurtman, Catecholamine synthesis: physiological coupling to precursor supply. *Biochemical Pharmacology* 1986; 35: 875-881.) As the Milner & Wurtman paper demonstrates, there is a very good reason for this: the end product of the reaction sequence, noradrenaline, feeds back to strongly inhibit the activity of tyrosine hydroxylase, a key rate-limiting enzyme in the  
30 synthesis of noradrenaline. As a result, under normal circumstances providing phenylalanine

or tyrosine will not influence noradrenaline production to any substantial degree. However, the situation changes when noradrenergic systems are activated or stressed. Under these circumstances tyrosine hydroxylase becomes phosphorylated and resistant to feedback inhibition by noradrenaline. As a result, in this situation the administration of phenylalanine or tyrosine does indeed activate noradrenaline synthesis (Milner and Wurtman). We propose that this is the explanation for the strong interaction we have observed between lofepramine and phenylalanine. In MS, the LC and LT noradrenergic systems are activated and stressed leading to loss of the feedback control of noradrenaline synthesis. As a result phenylalanine can enhance noradrenaline synthesis and strongly interact with lofepramine which inhibits uptake of released noradrenaline and so activates noradrenergic systems. We propose that a similar release of feedback inhibition occurs in any situation of brain injury, brain viral or other infections, including bacterial and prion infections, or chronic stress and that as a result the combination of a noradrenaline precursor and a noradrenergic drug will be beneficial in fatigue of any sort including fatigue after stroke, brain injury, migraine, MS, viral and other infections and chronic stress. We also suggest that the combination of a noradrenaline precursor and a noradrenergic drug will substantially enhance the rate and the degree of recovery from stroke or other brain damage.

#### Case History No.2

An example of this treatment is that of a 65 year old man who was apparently healthy experienced a small stroke which temporarily led to some loss of function in his left arm and left. The major part of the deficit recovered within a matter of days and within about six months there was no evidence of any residual specific sensorimotor problem apart from slight left arm weakness. However, over the month or so following the initial stroke the man became seriously depressed and fatigued, a state which he had not experienced before. He found it difficult to summon the energy to do anything. He also experienced the classic signs of depression with an unduly gloomy view of the impact of the stroke on his future life, an inability to take interest in things which had previously been a major part of his life, a strong sense of guilt about not spending enough time with his family prior to the stroke, and early morning wakening. He was treated first with imipramine, then with fluoxetine and then with

lofepramine without much success. Eventually 500mg of L-phenylalanine taken twice daily in the morning and evening was added to his 70mg bd dose of lofepramine. Within a week he began to feel better and within four weeks he appeared to be largely recovered. His energy had returned, he enjoyed his family and his view of his future prospects improved considerably. In this patient antidepressants alone were clearly inadequate to relieve either his depression or his fatigue but the addition of phenylalanine to lofepramine allowed resolution of most of his post-stroke problems.

#### MECHANISM

Phenylalanine



Tyrosine

↓ Tyrosine hydroxylase

3-dihydroxyphenylalanine



Dopamine



Noradrenaline

This unique mechanism thus activates the brain LC and LT systems particularly well when there is a need for activation as demonstrated by removal of the feedback inhibition of noradrenaline synthesis. In contrast, in normal situations when feedback inhibition is fully operative, the combination will not exert adverse effects because then the phenylalanine or

tyrosine will not be able to enhance noradrenaline synthesis. Because of a failure to understand this unique mechanism, although it has been proposed that phenylalanine and tyrosine may be used to treat depression, it has never been proposed that phenylalanine or tyrosine should be specifically combined with drugs which have specific effects on noradrenaline reuptake such as lofepramine, desipramine and reboxetine. Such combinations will be particularly effective in treating depression, especially when that depression is associated with chronic stress and abnormal function of the LC and LT systems.

The drugs which are most effective in the combination are those which have a large effect on the reuptake of noradrenaline at nerve endings and which at the same time have little effect or a much smaller effect on the uptake of serotonin. This can be demonstrated by studying the actions of the drugs on systems such as rat brain synaptosomes (C Bolden-Watson and E. Richelson, Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences 1993; 52: 1023-1029. C Sanchez and J Hyttel, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cellular and Molecular Neurobiology 1999; 19: 467-489). The most effective compounds will have a large effect on noradrenaline which is at the same time at least ten times larger than their effect on serotonin. Drugs which fall into this class include lofepramine, desipramine (also known as desmethylinipramine), nortriptyline, tomoxetine, maprotiline, oxaprotiline, levoprotiline, viloxazine and reboxetine. A second class of drugs which will have effects but which will be less active in selectively activating the LC and LT systems are the drugs which have combined actions on noradrenaline and serotonin reuptake or on noradrenaline and dopamine uptake. These drugs include venlafaxine, duloxetine, bupropion and milnacipran.

The key precursors which will be effective in a way which is appropriate to the state of the noradrenergic systems are the amino acids on the noradrenaline synthesis pathway which are before the rate-limiting regulated step of tyrosine hydroxylase. This means L-phenylalanine and L-tyrosine. The D forms of these amino acids may also have some activity since there is

some recent evidence that they can be converted into the L-forms which are the specific noradrenaline precursors by enzymes which are present in the brain.

The noradrenergic drug and the precursor may be formulated together in the same dosage form or may be presented in separate dosage forms but in the same pack using methods familiar to those skilled in the art. The dosage forms may include tablets, coated tablets, hard or soft gelatin capsules, liquids, gels, creams, suppositories, pessaries and parenteral formulations.

Because there is recent evidence that many people with chronic depression, chronic fatigue or chronic stress, or with brain damage of any sort may have inadequate levels of essential nutrients, the combinations may also be formulated with appropriate essential nutrients. Nutrients which are particularly important in brain function include folic acid, vitamin B12, vitamin B6 and tetrahydrobiopterin and related compounds.

### Examples

1. Tablets or capsules containing 50-100mg of lofepramine together with 100mg to 1000mg of phenylalanine, one to four to be taken each day.

2. As (1) but in which the lofepramine and phenylalanine are presented in separate dosage forms.

3. Tablets or capsules containing 50-100mg desipramine together with 100mg to 1000mg of phenylalanine, one to four to be taken each day.

4. As (3) but in which the desipramine and phenylalanine are presented in separate dosage forms.

5.     Tablets or capsules containing 2-5mg of reboxetine, together with 100mg to 1000mg of phenylalanine, one to four to be taken each day.
6.     As (5) but in which the reboxetine and phenylalanine are presented in separate dosage forms.
- 7-12. As 1-6 but in which the amino acid is tyrosine instead of phenylalanine.
13.    As 1-12 but in which the noradrenergic drug is any other selective noradrenaline reuptake inhibitor.
14.    As 1-12 but in which the drug is a compound which inhibits both noradrenaline and serotonin reuptake such as venlafaxine or milnacipram.
- 15    It will be appreciated that the formulations and treatments used according to the present invention are directed to the alleviation of the conditions specified hereinbefore independently of the presence of multiple sclerosis. However, they are of primary use in the treatment of patients who suffer from these conditions in the absence of multiple sclerosis.

## CLAIMS

- 5 1. The use of a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage forms or the same packs in the preparation of medication for the treatment of fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome.
- 10 2. The use according to claim 1, for the treatment of fatigue in any form.
3. The use according to claim 2, in which the fatigue is due to chronic fatigue syndrome or fibromyalgia or brain infections with any agent including viruses, prions or bacteria.
- 15 4. The use according to claim 2, in which the fatigue is due to brain injury or trauma of any sort or stroke of any sort.
5. The use according to claim 1, for assisting in the recovery of normal brain function after brain injury or stroke.
- 20 6. The use according to claim 1, for the treatment of medical conditions associated with chronic fatigue or fibromyalgia, and in particular for the treatment of irritable bowel syndrome.
- 25 7. The use according to claim 1, for the treatment of chronic stress for any reason.
8. The use according to claim 1, for the treatment of depression, and in particular chronic depression, or depression after brain injury, brain infection or stroke.

9. The use according to any of claims 1 to 8, in which the noradrenergic drug is selected from lofepramine, desipramine or reboxetine.
- 5 10. The use according to claim 9, in which the medication is formulated to provide from 50 to 100 mg of lofepramine or desipramine and from 100 to 1000 mg of phenylalanine or tyrosine, as a unit dose to be taken from 1 to 4 times daily.
- 10 11. The use according to claim 9, in which the medication is formulated to provide from 2 to 5 mg of reboxetine and from 100 to 1000 mg of phenylalanine or tyrosine as a unit dose to be taken from 1 to 4 times daily.
- 15 12. The use according to any of claims 1 to 8, in which the selective inhibitor is a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.
- 20 13. The use according to any of the preceding claims, in which the combination additionally contains other essential nutrients and in particular folic acid and related compounds, vitamin B12, vitamin B6 and tetrahydrobiopterin and related compounds.
- 25 14. A method of treatment of any of the conditions specified in any of the preceding claims using the combination of ingredients specified therein.
15. A composition for the treatment of any of the conditions specified in claim 1, comprising a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.